For Research Use Only

P27; KIP1 Monoclonal antibody

Catalog Number:67355-1-lg 3 Publications




Basic Information	Catalog Number: 67355-1-lg	GenBank Accession Number: BC001971	: Purification Method: Protein G purification	
	Size:	GenelD (NCBI):	CloneNo.:	
	150ul , Concentration: 1600 ug/ml by Nanodrop and 1000 ug/ml by Bradfor method using BSA as the standard;	1027	3F12C10	
		dUNIPROT ID:	Recommended Dilutions:	
		P46527	WB 1:5000-1:10000	
	Source: Mouse Isotype: IgG1 Immunogen Catalog Number: AG14634	Full Name:		
		cyclin-dependent kinase inhibitor 1B		
		(p27, Kip1)		
		Calculated MW: 198 aa, 22 kDa		
		Observed MW:		
		27 kDa		
Applications	Tested Applications:	Positive Controls:		
apprications and a second seco	WB, ELISA	WB, ELISA WB : Jurkat		
	Cited Applications: WB	cells		
	Species Specificity: Human, mouse, rat			
	Cited Species:			
	human, mouse			
Background Information	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subso from quiescence to the proliferative s	s to and prevents the activations ssion at G1. The degradation of equent ubiquitination by SCF tate. Downregulation of P27 H	hibitor, which shares a limited similarity with on of cyclin E-CDK2 or cyclin D-CDK4 complex of this protein, which is triggered by its CDK complexes, is required for the cellular transit has been implicated in the progression of seve livary cancer, oral squamous cell carcinomas,	
	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subso from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer.	s to and prevents the activations ssion at G1. The degradation of equent ubiquitination by SCF tate. Downregulation of P27 H	on of cyclin E-CDK2 or cyclin D-CDK4 complex of this protein, which is triggered by its CDK complexes, is required for the cellular transit has been implicated in the progression of seve	
	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 binds and thus controlling cell cycle progress dependent phosphorylation and subso from quiescence to the proliferative so malignancies, including lung cancer, gastric cancer.	s to and prevents the activation ssion at G1. The degradation of equent ubiquitination by SCF tate. Downregulation of P27 h hepatocellular carcinoma, sal	on of cyclin E-CDK2 or cyclin D-CDK4 complex of this protein, which is triggered by its CDK complexes, is required for the cellular transit has been implicated in the progression of seve livary cancer, oral squamous cell carcinomas, Application	
Background Information Notable Publications	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subsi- from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer. Author Pub Xin Zhou 347	s to and prevents the activation ssion at G1. The degradation of equent ubiquitination by SCF tate. Downregulation of P27 H hepatocellular carcinoma, sal med ID Journal	on of cyclin E-CDK2 or cyclin D-CDK4 complex of this protein, which is triggered by its CDK complexes, is required for the cellular transit has been implicated in the progression of seve livary cancer, oral squamous cell carcinomas, Application	
	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subsi- from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer.AuthorPub Xin ZhouXin Zhou347Tongguan Tian379	s to and prevents the activation ssion at G1. The degradation of equent ubiquitination by SCF tate. Downregulation of P27 H hepatocellular carcinoma, sale med ID Journal 65572 J Hepatocell	on of cyclin E-CDK2 or cyclin D-CDK4 complex of this protein, which is triggered by its CDK complexes, is required for the cellular transit has been implicated in the progression of seve livary cancer, oral squamous cell carcinomas, Application Carcinoma WB	
Notable Publications	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subsi- from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer.AuthorPub Xin ZhouXin Zhou347Tongguan Tian379Wei Chang376	st to and prevents the activation of the section of the degradation of the equent ubiquitination by SCF state. Downregulation of P27 hepatocellular carcinoma, sale med ID Journal 65572 J Hepatocell 38970 Cell Rep	on of cyclin E-CDK2 or cyclin D-CDK4 complex of this protein, which is triggered by its CDK complexes, is required for the cellular transit has been implicated in the progression of seve livary cancer, oral squamous cell carcinomas, Application I Carcinoma WB WB	
Notable Publications	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subsi- from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer.AuthorPub Xin ZhouXin Zhou347Tongguan Tian379	st to and prevents the activation of the section of the degradation of the equent ubiquitination by SCF state. Downregulation of P27 hepatocellular carcinoma, sale med ID Journal 65572 J Hepatocell 38970 Cell Rep	on of cyclin E-CDK2 or cyclin D-CDK4 complex of this protein, which is triggered by its CDK complexes, is required for the cellular transit has been implicated in the progression of seve livary cancer, oral squamous cell carcinomas, Application I Carcinoma WB WB	
Notable Publications	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subsi- from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer. Author Pub Xin Zhou 347 Tongguan Tian 379 Wei Chang 376 Storage: Storage Suffer:	s to and prevents the activation ssion at G1. The degradation of equent ubiquitination by SCF tate. Downregulation of P27 H hepatocellular carcinoma, sal med ID Journal 65572 J Hepatocell 38970 Cell Rep 43584 J Vasc Res	on of cyclin E-CDK2 or cyclin D-CDK4 complex of this protein, which is triggered by its CDK complexes, is required for the cellular transit has been implicated in the progression of seve livary cancer, oral squamous cell carcinomas, Application I Carcinoma WB WB	
	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subso from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer. Author Pub Xin Zhou 347 Tongguan Tian 379 Wei Chang 376 Storage: Storage Buffer: PBS with 0.02% sodium azide and 500	s to and prevents the activation ssion at G1. The degradation of equent ubiquitination by SCF tate. Downregulation of P27 H hepatocellular carcinoma, sal med ID Journal (65572 J Hepatocell (38970 Cell Rep (43584 J Vasc Res % glycerol pH 7.3.	on of cyclin E-CDK2 or cyclin D-CDK4 complex of this protein, which is triggered by its CDK complexes, is required for the cellular transit has been implicated in the progression of seve livary cancer, oral squamous cell carcinomas, Application I Carcinoma WB WB	
Notable Publications	DKN1B, also named as P27 or KIP1, is CDK inhibitor CDKN1A/p21. P27 bind: and thus controlling cell cycle progres dependent phosphorylation and subsi- from quiescence to the proliferative s malignancies, including lung cancer, gastric cancer. Author Pub Xin Zhou 347 Tongguan Tian 379 Wei Chang 376 Storage: Storage Suffer:	s to and prevents the activation ssion at G1. The degradation of equent ubiquitination by SCF tate. Downregulation of P27 H hepatocellular carcinoma, sale med ID Journal (65572 J Hepatocell (38970 Cell Rep (43584 J Vasc Res % glycerol pH 7.3.	on of cyclin E-CDK2 or cyclin D-CDK4 complex of this protein, which is triggered by its CDK complexes, is required for the cellular transit has been implicated in the progression of seve livary cancer, oral squamous cell carcinomas, Application I Carcinoma WB WB	

For technical support and original validation data for this product please contact:T: 1 (888) 4PTGLAB (1-888-478-4522) (toll freeE: proteintech@ptglab.comin USA), or 1(312) 455-8498 (outside USA)W: ptglab.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.

Selected Validation Data



Jurkat cells were subjected to SDS PAGE followed by western blot with 67355-1-1g (P27; KIP1 antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours.